knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 00:07:12 - browse：2943

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Obesity now affects over 1 billion people worldwide, study finds

WSS

Covid isolation guidance eased by the CDC

Morgan Health, with ambitious aims, wants you to know it’s still here

Feng Zhang CRISPR delivery startup lays off quarter of staff

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

An inside look at PIPEs, biotech's buzzy new financing tool

Wikipedia

knowledge

explore

Hollywood unions extend contract negotiations for actors

Obesity now affects over 1 billion people worldwide, study finds

How to save PrEP access — and even expand it

RaDonda Vaught to speak at CommonSpirit event on patient safety

Wildfire smoke exposes gaps in outdoor worker protections

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Virginia high school admissions case could be legal follow

How to address the problem of discarded donor organs

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Federal weight loss drug coverage is 30 years out of date

hotspot

The FDA must approve intranasal treatments for anaphylaxis

J&J to buy cancer drug developer Ambrx Biopharma

Ahead of JPM, here's who's profiting most in health care

Feng Zhang, Grail founder join forces on new gene editing startup

Pfizer highlights cancer drugs it thinks could reignite investor interest

The biotech scorecard for Q1: 17 stock

knowledge

leisure time

hotspot

hotspot